===
EQS-News: APONTIS PHARMA AG / Key word(s): Personnel
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of
the Company
2024-06-27 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of
the Company
Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company
specializing in Single Pill combinations in the German market, expands its Executive Board with a view to the Company's
strategic development. To reflect the growing portfolio of single pill combinations, the future internationalization of
the Company and the upcoming further development of the ESG strategy, the Finance department within the Executive Board
will be strengthened. With effect from 1 July 2024, the Supervisory Board appointed CFO Thomas Zimmermann to the
Executive Board with a contract term until 30 June 2027.
Thomas Zimmermann has been CFO of the APONTIS PHARMA Group since 1 January 2022. Since then, he has further developed
the finance department and played a key role in the realignment of the company from September 2023. He will strengthen
the Executive Board team sustainably and be responsible for Finance, Investor Relations, Compliance, Contract
Management, IT and ESG.
Dr. Matthias Wiedenfels, Chairman of the Supervisory Board of APONTIS PHARMA AG: "Thomas Zimmermann is a proven
financial expert with strong pharmaceutical expertise and is very familiar with the corporate processes of APONTIS
PHARMA. He has played a decisive role in shaping the realignment of the Company. With the increasing number of Single
Pill combinations, the future internationalization of the Company and the strengthening of our positive contribution to
ESG, we are pleased to establish a strong finance department at Management Board level."
Thomas Zimmermann, designated member of the Executive Board of APONTIS PHARMA AG: "I am very honored about the trust
placed in me and the opportunity to drive the further development of APONTIS PHARMA together with Bruno Wohlschlegel
and Thomas Milz as well as the entire team. In doing so, I will continue to focus on efficient and lean processes and
expand this to include effective risk and contract management in preparation of the future internationalization."
Additional information:
Information on upcoming events can be found at https://apontis-pharma.de/en/financial-calendar and the latest analyst
assessments at https://apontis-pharma.de/en/share-price.
About APONTIS PHARMA:
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills
combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies
have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and
quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill
combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and
Germany. APONTIS PHARMA has been developing, promoting, and distributing a broad portfolio of Single Pill combinations
and other pharmaceutical products since 2013, with a special focus on cardiovascular diseases such as hypertension,
hyperlipidemia, and secondary prevention. For additional information about APONTIS PHARMA, please visit
www.apontis-pharma.de.
APONTIS PHARMA AG
Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim / Rhein
Germany
apontis-pharma.de
APONTIS PHARMA Press Contact
CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330
2024-06-27 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      APONTIS PHARMA AG 

Rolf-Schwarz-Schütte-Platz 1
40789 Monheim am Rhein
Germany

E-mail:       ir@apontis-pharma.de 
Internet:     https://apontis-pharma.de/ 
ISIN:         DE000A3CMGM5 
WKN:          A3CMGM 
Listed:       Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate 

Exchange
EQS News ID: 1931745

End of News EQS News Service
===
1931745 2024-06-27 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1931745&application_name=news

END) Dow Jones Newswires

June 27, 2024 01:30 ET (05:30 GMT)